drugset / Trial / NCT06420765

A Microneurography Study of NaV1.8 Inhibition in Healthy Adults

NCT06420765

Phase 1 Completed 92 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study is to determine the effects of Nav1.8 inhibition on activity-dependent slowing (ADS) of C-nociceptor nerve fibers, evoked action potential (AP) conduction velocity of C-nociceptor nerve fibers using VX-150, VX-993 and VX-548.

Timeline

Start
2024-05-21
Primary completion
2025-03-22
Completion
2025-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Suzetrigine Small molecule Oral
Subject VX-150 Unknown Oral
Subject VX-993 Unknown Oral

Indications

No indication recorded.